TrialNature communications2026

Dalpicilib combined with cetuximab in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma: A phase II trial.

Houyu Ju et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.